Camurus AB
7CA
Company Profile
Business description
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
Contact
Ideon Science Park
LundSE-223 70
SWET: +46 462865730
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
256
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
4 factors that led to the incredible returns of Philip Morris.
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,089.90 | 7.80 | 0.10% |
| CAC 40 | 8,109.24 | 35.26 | 0.44% |
| DAX 40 | 23,417.28 | 262.71 | 1.13% |
| Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
| FTSE 100 | 8,719.14 | 38.85 | 0.45% |
| HKSE | 24,740.57 | 595.00 | 2.46% |
| NASDAQ | 17,808.66 | 505.65 | 2.92% |
| Nikkei 225 | 37,845.42 | 448.90 | 1.20% |
| NZX 50 Index | 12,076.85 | 189.40 | -1.54% |
| S&P 500 | 5,638.94 | 117.42 | 2.13% |
| S&P/ASX 200 | 7,860.40 | 6.30 | 0.08% |
| SSE Composite Index | 3,429.76 | 3.63 | 0.11% |